Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial.
Vay M, Meyer MJ, Blank A, Skopp G, Rose P, Tzvetkov MV, Mikus G.
Vay M, et al.
Clin Pharmacokinet. 2020 Jul;59(7):927-939. doi: 10.1007/s40262-020-00862-6.
Clin Pharmacokinet. 2020.
PMID: 32060866
Free PMC article.
Clinical Trial.
CONCLUSIONS: The pharmacokinetics of yohimbine were highly correlated with CYP2D6, which was further supported by the clearance inhibition caused by the CYP2D6 inhibitor paroxetine. With these data, yohimbine is proposed to be a suitable probe drug to predict CYP2D6 activi …
CONCLUSIONS: The pharmacokinetics of yohimbine were highly correlated with CYP2D6, which was further supported by the clearance inhibition c …